PCR Stock Overview
PCC Rokita SA manufactures and distributes chemical products in Poland and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
PCC Rokita SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | zł104.00 |
52 Week High | zł152.20 |
52 Week Low | zł81.10 |
Beta | 1.17 |
1 Month Change | 9.47% |
3 Month Change | 11.83% |
1 Year Change | -25.29% |
3 Year Change | 50.72% |
5 Year Change | 17.12% |
Change since IPO | 213.63% |
Recent News & Updates
Recent updates
Is PCC Rokita (WSE:PCR) Using Too Much Debt?
Aug 24PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 29Is PCC Rokita (WSE:PCR) A Risky Investment?
Jan 18PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23
Apr 16Why We Like The Returns At PCC Rokita (WSE:PCR)
Mar 19What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?
Jan 25We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)
Sep 01Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching
Jun 14Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?
May 18Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes
Apr 13Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem
Mar 23PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Mar 09Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?
Feb 19What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?
Feb 04Is PCC Rokita (WSE:PCR) Using Too Much Debt?
Jan 15Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?
Dec 30Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years
Dec 17PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Dec 03Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?
Nov 20Shareholder Returns
PCR | PL Chemicals | PL Market | |
---|---|---|---|
7D | -0.6% | -1.1% | 2.3% |
1Y | -25.3% | -18.4% | 35.3% |
Return vs Industry: PCR underperformed the Polish Chemicals industry which returned -17.5% over the past year.
Return vs Market: PCR underperformed the Polish Market which returned 35.7% over the past year.
Price Volatility
PCR volatility | |
---|---|
PCR Average Weekly Movement | 3.1% |
Chemicals Industry Average Movement | 3.9% |
Market Average Movement | 5.0% |
10% most volatile stocks in PL Market | 9.5% |
10% least volatile stocks in PL Market | 3.2% |
Stable Share Price: PCR has not had significant price volatility in the past 3 months.
Volatility Over Time: PCR's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 1,446 | Wieslaw Klimkowski | https://www.pcc.rokita.pl |
PCC Rokita SA manufactures and distributes chemical products in Poland and internationally. The company offers chlorine and alkali; polyurethanes; household chemicals and cleaning agents; washing preparations; liquid chemicals and disinfectants; vegan body and hair care products; shower gels, hair shampoos, and liquid soaps; flexible foams; and organic products, as well as polyols, naphthalene, and phosphorus derivatives. The company also provides specialty products, including anionic surfactants, alkoxylated fatty alcohols, non-ionic surfactants, synthetic and foam-forming extinguishing agents, synthetic base oils and additives, polyester polyols, chemical raw materials, polyurethane adhesives, prepolymers, polymeric polyols, and polyether polyols.
PCC Rokita SA Fundamentals Summary
PCR fundamental statistics | |
---|---|
Market cap | zł2.06b |
Earnings (TTM) | zł267.84m |
Revenue (TTM) | zł2.39b |
7.7x
P/E Ratio0.9x
P/S RatioIs PCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PCR income statement (TTM) | |
---|---|
Revenue | zł2.39b |
Cost of Revenue | zł1.80b |
Gross Profit | zł584.25m |
Other Expenses | zł316.41m |
Earnings | zł267.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
Earnings per share (EPS) | 13.49 |
Gross Margin | 24.46% |
Net Profit Margin | 11.22% |
Debt/Equity Ratio | 37.9% |
How did PCR perform over the long term?
See historical performance and comparison